Last reviewed · How we verify
L-Serine
L-Serine is a non-essential amino acid that serves as a precursor for neurotransmitter and phospholipid synthesis, supporting neurological function and cell membrane integrity.
L-Serine is a non-essential amino acid that serves as a precursor for neurotransmitter and phospholipid synthesis, supporting neurological function and cell membrane integrity. Used for Serine deficiency disorders, Neurological support in various conditions.
At a glance
| Generic name | L-Serine |
|---|---|
| Also known as | amino acid supplementation with L-serine |
| Sponsor | Elijah W. Stommel |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
L-Serine is a proteinogenic amino acid that acts as a building block for proteins and as a precursor for the synthesis of sphingolipids, phosphatidylserine, and the neurotransmitter glycine. It plays critical roles in nervous system development, myelin formation, and cellular signaling. L-Serine supplementation is used to address deficiencies in serine synthesis or metabolism, particularly in neurological conditions.
Approved indications
- Serine deficiency disorders
- Neurological support in various conditions
Common side effects
- Gastrointestinal disturbance
- Nausea
Key clinical trials
- Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing (NA)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Cognitive Strategies in Early Psychosis 2 (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Serine CI brief — competitive landscape report
- L-Serine updates RSS · CI watch RSS
- Elijah W. Stommel portfolio CI